Zogenix down on heavy volume

|By:, SA News Editor

Shares of Zogenix (ZGNX) currently trade down 10% on double normal volume in response to yesterday's post close earnings report.

Its recently-approved opioid drug, Zohydro, is controversial due to its perceived abuse potential.

The company did not provide revenue guidance for 2014. It did disclose that it expects R&D and SG&A expenses to come in at $110M - $120M.